AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06095908
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacain administered with two different ways to the patients, postoperative pain recorded
Trial: NCT05898256
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg administered intravenously (IV)
Trial: NCT05898256
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 g/m2, administered as an IV infusion within 30 minutes
Trial: NCT05898256
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg/m2, administered as an IV infusion over 4 hours
Trial: NCT05423951
Drug: REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]
RxNorm normalized name: remimazolam besylate 2.5 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [BYFAVO]
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For the induction of anesthesia, patients allocated to the remimazolam group will receive intravenous infusion of remimazolam at a rate of 6 mg/kg/h, followed by 1 mg/kg/h after the loss of consciousness. The infusion rate of remimazolam will be adjusted to a maximum rate of 2 mg/kg/h to achieve a bispectral index of 40 to 60.
Trial: NCT05423951
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For the induction of anesthesia, patients allocated to the propofol group will receive a bolus dose of propofol 1.5 mg/kg. After the loss of consciousness, general anesthesia will be maintained with sevoflurane to achieve a bispectral index of 40 to 60.
Trial: NCT05423951
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the loss of consciousness, a bolus of rocuronium 1 mg/kg was intravenously administered. After 90 seconds of manual ventilation, endotracheal intubation was performed
Trial: NCT05008861
Drug: Platinum based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of Platinum based Chemotherapy every 3 weeks.
Trial: NCT04421248
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In ADHD participants only: blinded, randomized, placebo-controlled single dose, crossover on separate days separated by at least one week.
Trial: NCT06424626
Drug: AK104+Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receive AK104 10mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.
Trial: NCT06424626
Drug: AK112+Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receive AK112 20mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.
Trial: NCT05884151
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A 30 patients treated with Intradermal Tranexamic acid injection (4mg/ml) for preparation an insulin syringe was used with a volume of 1ml containing 0.04 ml of TXA and the reminder being normal saline to ensure 4mg preparation in each insulin syringe
Trial: NCT05884151
Drug: Platelets rich plasma
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B 30 patients prescribed with PRP (1ml) intra-dermally PRP was obtained manually by a two-step procedure using a centrifuge machine. First spin was performed at 1500 RPM for 10 minutes. Second spin was performed at 4000 RPM for 10 minutes. Thus, obtaining a two-part plasma. Upper two third was platelet poor plasma and was discarded. Lower one third was platelets rich plasma. Before injection applying 0.1 ml calcium chloride was added for each 1 ml of PRP to activate the platelets. PRP was injected 1 ml by using 30 G needle (insulin syringe) in each cm2 of melasma.
Trial: NCT04834362
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients treated with human insulin regimen will receive 50% of total daily dose as NPH insulin at around 6 am and 6 pm, while the rest 50% regular human insulin three times a day in 3 equally divided doses at around 6 am, 12 pm and 6 pm.
Trial: NCT05202236
Drug: pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The patients will receive 13.5 mg (1 pill/time) of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen, with 21 days as a cycle. They should take pemigatinib at regular times of the day to avoid the effects of inconsistent timing on plasma concentrations.
Trial: NCT06410443
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Retention enema with 10mg dexamethasone, once a day, the total course of treatment for 1 week.
Trial: NCT05448781
Drug: Endostatin
RxNorm normalized name: Endostatin
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients with advanced NSCLC were treated with endostatin combined with Tirelizumab and platinum-containing two-drug chemotherapy.26 cases of non-squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Pemetrexed+Carboplatin. and 12 cases of squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Paclitaxel/Albumin paclitaxel+Carboplatin,The maintenance treatment phase was continuous treatment with Endu combined with Tirelizumab
Trial: NCT06427499
Drug: Stannous fluoride toothpaste
RxNorm normalized name: stannous fluoride Toothpaste
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: brush 2 min morning \& night daily
Trial: NCT06427499
Drug: Colgate Cavity Protection Toothpaste
RxNorm normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: brush 2 min morning \& night daily
Trial: NCT05154344
Drug: Capmatinib
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Available through expanded access
Trial: NCT06373848
Drug: Receive 30 mg of Coq10
RxNorm normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A total of 120 individuals diagnosed with chronic periodontitis were selected for this study. These participants were randomly assigned to two different groups. The purpose of the study was to measure the periodontal parameters of the two molars adjacent to the mandible using a periodontal probe. All of the patients received scaling and root planing (SRP) as part of their treatment. However, the treatment groups differed in terms of the supplements they received. Group A was given a daily dose of Coq10 at 30 mg, while Group B received a daily dose of Vitamin E at 400 mg; Furthermore, group C did not receive any supplements. The periodontal examination involved a total of 300 teeth across the three groups. In addition to this, 2 ml of unstimulated saliva was collected from each patient both before and after 2 months. The purpose of collecting the saliva samples was to evaluate the total antioxidant capacity and determine if there were any changes over time.
Trial: NCT04609540
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dual anti-HER2 therapy
Trial: NCT04822298
Drug: AMG 160
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 160 administered as an intravenous (IV) infusion
Trial: NCT05778877
Drug: SEL-302
RxNorm normalized name: SEL-302
DrugBank: SEL-302 (DB18434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEL-302 Drug: MMA-101 (1.0E13 vg/kg)~Drug: SEL-110 (0.15 mg/kg or up to 0.3 mg/kg)~Other Names:~SEL-110.36, ImmTOR
Trial: NCT05207865
Drug: Rimegepant
RxNorm normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rimegepant ODT 75mg daily
Trial: NCT05466708
Drug: Esketamine combined with dexmedetomidine
RxNorm normalized name: esketamine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Esketamine, injection, 50mg/ bottle, source: hospital pharmacy, production unit: Jiangsu Hengrui Pharmaceutical Co., LTD., validity: 2 years, storage condition: airtight shading, room temperature.~Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature.
Trial: NCT05466708
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature.
Trial: NCT06610071
Drug: ICG administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group.
Trial: NCT06610071
Drug: ICG administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
Trial: NCT06610071
Drug: ICG administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group
Trial: NCT06609447
Drug: Vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will start combined therapy with vedolizumab and VSL#3 or placebo at the same time. Vedolizumab will be administered according to clinical practice with the following schedule: 300 mg intravenously on Baseline (Day 1 / Week 0) and Weeks 2, 6, and 14, with a flexibility of ±3 days relative to the start of VSL#3 administration.
Trial: NCT05220124
Drug: Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 420mg Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) bid for 4 treatment cycles.
Trial: NCT06132126
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC.
Trial: NCT05657717
Drug: Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
Trial: NCT05302388
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg, intramuscular injection.These were administered within 30 minutes prior to infusion of the experimental drug.
Trial: NCT06120725
Drug: Ticagrelor 90 MG
RxNorm normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Trial: NCT06120725
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Trial: NCT02937376
Drug: N-acetyl cystein
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A trial of exercise before and after 4 weeks of N-acetyl cystein (NAC) supplementation.
Trial: NCT05130424
Drug: Herombopag
RxNorm normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herombopag in the treatment of thrombocytopenia-related diseases Non-interventional clinical research.Do not interfere with the dosage and market of Hetrobopar Oral medication
Trial: NCT06435013
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;
Trial: NCT04942730
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2/day iv x 6 days, days -7 through -2 of HSCT
Trial: NCT04942730
Drug: Bendamustine Hydrochloride
RxNorm normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m2 iv x 2 days, Days -7 through -6 of HSCT
Trial: NCT04942730
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mg/kg po qid x 3 days, Days -5 through -3
Trial: NCT04942730
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days, Days +5 through +35
Trial: NCT00270023
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04942730
Drug: Tacrolimus 5Mg Cap
RxNorm normalized name: TACROLIMUS 5MG CAP
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.03 mg/kg/day iv or po, Days +5 through +100 with with further correction by concentration. Target concentration 5-15 ng/ml.
Trial: NCT05142228
Drug: Erenumab-Aooe
RxNorm normalized name: erenumab-aooe
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
Trial: NCT05208866
Drug: Lixivaptan
RxNorm normalized name: Lixivaptan
DrugBank: Lixivaptan (DB06666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vasopressin V2 receptor antagonist
Trial: NCT04698941
Drug: Albumin Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Albumin Paclitaxel intravenous infusion was administered at a dose of 260 mg/m\^2 on Day 1 of each 21-day cycle.
Trial: NCT05363202
Drug: Fluticasone propionate Inhalation Aerosol 44 mcg
RxNorm normalized name: Fluticasone Propionate Inhalation Aerosol
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
Trial: NCT05363202
Drug: FLOVENT HFA 44 mcg
RxNorm normalized name: Flovent HFA 44 MCG/ACTUAT Metered Dose Inhaler, 60 ACTUAT
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
Trial: NCT05516550
Drug: Treamid
RxNorm normalized name: Treamid
DrugBank: Treamid (DB16365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Treamid 25 mg once a day daily during 4 weeks
Trial: NCT05516550
Drug: Treamid twice a day
RxNorm normalized name: Tice BCG
DrugBank: Treamid (DB16365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Treamid 25 mg in the morning and in the evening daily during 4 weeks
Trial: NCT05516550
Drug: Treamid once a day
RxNorm normalized name: Treamid
DrugBank: Treamid (DB16365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Treamid 50 mg in the morning daily during 4 weeks
Trial: NCT05556005
Drug: Trimetazidine Dihydrochloride
RxNorm normalized name: trimetazidine dihydrochloride
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine Dihydrochloride 35 mg modified release tablet used twice daily
Trial: NCT05309343
Drug: Chinese patent medicine
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill, etc.
Trial: NCT03259698
Drug: nPEP
RxNorm normalized name: Zenpep
DrugBank: Galinpepimut-S (DB17271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Bictegravir/emtricitabine/tenofovir alafenamide 50/200/25mg (Biktarvy®) one tablet once daily as study drug to complete a 28 day course of PEP.
Trial: NCT06382961
Drug: Dexmedetomidine injection
RxNorm normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combining with 3 μg.kg-1 sufentanil, 3 μg.kg-1 dexmedetomidine is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
Trial: NCT04917692
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2.5 mg daily
Trial: NCT06526728
Drug: Hyperbaric oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be subjected to seven once-daily sessions of hyperbaric oxygen therapy. Each session will last 115-120 minutes whereby the chambre will be pressurized to 2.4 ATA during which participants will breathe 100% (pure) oxygen.
Trial: NCT05468203
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
Trial: NCT00000926
Drug: Nonoxynol-9
RxNorm normalized name: Nonoxynol-9
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00227474
Drug: recombinant modified vaccinia Ankara-5T4 vaccine
RxNorm normalized name: Modified vaccinia ankara
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04675151
Drug: Phentolamine Ophthalmic Solution 0.75%
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Trial: NCT04675151
Drug: Pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine ophthalmic solution
Trial: NCT00002301
Drug: Foscarnet sodium
RxNorm normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04668144
Drug: Cangrelor
RxNorm normalized name: Cangrelor
DrugBank: Cangrelor (DB06441)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The total infusion will last 2 hours.
Trial: NCT04668144
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prasugrel will be used in line with FDA recommendations using a 60mg LD followed by a 10mg daily maintenance dose started 24 hours after LD administration
Trial: NCT04651348
Drug: Recombinant Humanized Monoclonal Antibody MIL95
RxNorm normalized name: Recombinant humanized monoclonal antibody 5c8
DrugBank: Ruplizumab (DB06475)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PART A :The patients confirming to the eligibility criteria will be assigned to the 4 dose groups (0.1mg/kg, 0.3mg/kg, 0.8mg/kg, 1.0mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL95 every week on Day 1 for a maximum of Twelve weeks.~PART B:One recommended dose as a priming dose will be selected from 4 dose groups(0.1mg/kg、0.3mg/kg、0.8mg/kg、1.0mg/kg) based on results of PART A. Each patient will receive a priming dose of MIL95 on Day 1 Cycle 1.The patients will be assigned to the 5 maintenance dose groups (3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 45mg/kg, respectively) based on the sequence of inclusion. The maintenance dose was given on Day 8,15,22 Cycle 1 and on Day 1,8,15,22 Cycle 2+. Each cycle was 28 days.
Trial: NCT05027997
Drug: Dipraglurant
RxNorm normalized name: Dipraglurant
DrugBank: Dipraglurant (DB12733)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT00000965
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06140186
Drug: Topical Timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month.
Trial: NCT06140186
Drug: Betamethasone Valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate 0.1% cream application twice daily
Trial: NCT04807829
Drug: Nabilone
RxNorm normalized name: Nabilone
DrugBank: Nabilone (DB00486)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nabilone is a synthetic endocannabinoid and CB1 agonist.